<?xml version="1.0" encoding="UTF-8"?>
<collection xmlns="http://www.loc.gov/MARC21/slim">
    <record>
        <controlfield tag="001">78341</controlfield>
        <controlfield tag="005">20200217133051.0</controlfield>
        <datafield tag="024" ind1="7" ind2=" ">
            <subfield code="2">doi</subfield>
            <subfield code="a">10.1016/j.drudis.2018.01.031</subfield>
        </datafield>
        <datafield tag="024" ind1="8" ind2=" ">
            <subfield code="2">sideral</subfield>
            <subfield code="a">105480</subfield>
        </datafield>
        <datafield tag="037" ind1=" " ind2=" ">
            <subfield code="a">ART-2018-105480</subfield>
        </datafield>
        <datafield tag="041" ind1=" " ind2=" ">
            <subfield code="a">eng</subfield>
        </datafield>
        <datafield tag="100" ind1=" " ind2=" ">
            <subfield code="0">(orcid)0000-0002-0269-7337</subfield>
            <subfield code="a">Ruiz-Pesini, E.</subfield>
            <subfield code="u">Universidad de Zaragoza</subfield>
        </datafield>
        <datafield tag="245" ind1=" " ind2=" ">
            <subfield code="a">Increasing mtDNA levels as therapy for mitochondrial optic neuropathies</subfield>
        </datafield>
        <datafield tag="260" ind1=" " ind2=" ">
            <subfield code="c">2018</subfield>
        </datafield>
        <datafield tag="506" ind1="0" ind2=" ">
            <subfield code="a">Access copy available to the general public</subfield>
            <subfield code="f">Unrestricted</subfield>
        </datafield>
        <datafield tag="520" ind1="3" ind2=" ">
            <subfield code="a">Leber hereditary optic neuropathy (LHON) is a rare, inherited mitochondrial disease. No treatment has shown a clear-cut benefit on a clinically meaningful end-point. Primary open-angle glaucoma (POAG) is a frequent, acquired optic neuropathy. Lowering intraocular pressure (IOP) reduces disease progression. However, current methods to decelerate this progression are recognized as being inadequate. Therefore, there is a clear need to look for new therapeutic approaches. The growing evidence indicates that POAG can also be a mitochondrial optic neuropathy (MON). Several risk elements are common for both diseases and all of them decrease mitochondrial (mt)DNA content. Based on these susceptibility factors and their molecular mechanism, we suggest herein pharmacological therapies targeted to increase mtDNA levels, oxidative phosphorylation (OXPHOS) capability, and mitochondrial energy production as treatments for MONs.</subfield>
        </datafield>
        <datafield tag="536" ind1=" " ind2=" ">
            <subfield code="9">info:eu-repo/grantAgreement/ES/DGA/B33</subfield>
            <subfield code="9">info:eu-repo/grantAgreement/ES/DGA/FEDER</subfield>
            <subfield code="9">info:eu-repo/grantAgreement/ES/ISCIII/PI14-00070</subfield>
            <subfield code="9">info:eu-repo/grantAgreement/ES/ISCIII/PI17-00021</subfield>
            <subfield code="9">info:eu-repo/grantAgreement/ES/ISCIII/PI17-00166</subfield>
            <subfield code="9">info:eu-repo/grantAgreement/ES/ISCIII/P114-00005</subfield>
        </datafield>
        <datafield tag="540" ind1=" " ind2=" ">
            <subfield code="9">info:eu-repo/semantics/openAccess</subfield>
            <subfield code="a">by-nc-nd</subfield>
            <subfield code="u">http://creativecommons.org/licenses/by-nc-nd/3.0/es/</subfield>
        </datafield>
        <datafield tag="590" ind1=" " ind2=" ">
            <subfield code="a">6.88</subfield>
            <subfield code="b">2018</subfield>
        </datafield>
        <datafield tag="591" ind1=" " ind2=" ">
            <subfield code="a">PHARMACOLOGY &amp; PHARMACY</subfield>
            <subfield code="b">12 / 266 = 0.045</subfield>
            <subfield code="c">2018</subfield>
            <subfield code="d">Q1</subfield>
            <subfield code="e">T1</subfield>
        </datafield>
        <datafield tag="592" ind1=" " ind2=" ">
            <subfield code="a">2.248</subfield>
            <subfield code="b">2018</subfield>
        </datafield>
        <datafield tag="593" ind1=" " ind2=" ">
            <subfield code="a">Pharmacology</subfield>
            <subfield code="c">2018</subfield>
            <subfield code="d">Q1</subfield>
        </datafield>
        <datafield tag="593" ind1=" " ind2=" ">
            <subfield code="a">Drug Discovery</subfield>
            <subfield code="c">2018</subfield>
            <subfield code="d">Q1</subfield>
        </datafield>
        <datafield tag="655" ind1=" " ind2="4">
            <subfield code="a">info:eu-repo/semantics/article</subfield>
            <subfield code="v">info:eu-repo/semantics/acceptedVersion</subfield>
        </datafield>
        <datafield tag="700" ind1=" " ind2=" ">
            <subfield code="0">(orcid)0000-0001-5964-6138</subfield>
            <subfield code="a">Emperador, S.</subfield>
            <subfield code="u">Universidad de Zaragoza</subfield>
        </datafield>
        <datafield tag="700" ind1=" " ind2=" ">
            <subfield code="0">(orcid)0000-0002-3217-1424</subfield>
            <subfield code="a">López-Gallardo, E.</subfield>
            <subfield code="u">Universidad de Zaragoza</subfield>
        </datafield>
        <datafield tag="700" ind1=" " ind2=" ">
            <subfield code="0">(orcid)0000-0003-3524-5158</subfield>
            <subfield code="a">Hernández-Ainsa, C.</subfield>
            <subfield code="u">Universidad de Zaragoza</subfield>
        </datafield>
        <datafield tag="700" ind1=" " ind2=" ">
            <subfield code="0">(orcid)0000-0003-1770-6299</subfield>
            <subfield code="a">Montoya, J.</subfield>
            <subfield code="u">Universidad de Zaragoza</subfield>
        </datafield>
        <datafield tag="710" ind1="2" ind2=" ">
            <subfield code="1">1003</subfield>
            <subfield code="2">443</subfield>
            <subfield code="a">Universidad de Zaragoza</subfield>
            <subfield code="b">Dpto. Anatom.Histolog.Humanas</subfield>
            <subfield code="c">Area Histología</subfield>
        </datafield>
        <datafield tag="710" ind1="2" ind2=" ">
            <subfield code="1">1002</subfield>
            <subfield code="2">060</subfield>
            <subfield code="a">Universidad de Zaragoza</subfield>
            <subfield code="b">Dpto. Bioq.Biolog.Mol. Celular</subfield>
            <subfield code="c">Área Bioquímica y Biolog.Mole.</subfield>
        </datafield>
        <datafield tag="773" ind1=" " ind2=" ">
            <subfield code="g">23, 3 (2018), 493-498</subfield>
            <subfield code="p">Drug discov. today</subfield>
            <subfield code="t">DRUG DISCOVERY TODAY</subfield>
            <subfield code="x">1359-6446</subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2=" ">
            <subfield code="s">420347</subfield>
            <subfield code="u">http://zaguan.unizar.es/record/78341/files/texto_completo.pdf</subfield>
            <subfield code="y">Postprint</subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2=" ">
            <subfield code="s">43759</subfield>
            <subfield code="u">http://zaguan.unizar.es/record/78341/files/texto_completo.jpg?subformat=icon</subfield>
            <subfield code="x">icon</subfield>
            <subfield code="y">Postprint</subfield>
        </datafield>
        <datafield tag="909" ind1="C" ind2="O">
            <subfield code="o">oai:zaguan.unizar.es:78341</subfield>
            <subfield code="p">articulos</subfield>
            <subfield code="p">driver</subfield>
        </datafield>
        <datafield tag="951" ind1=" " ind2=" ">
            <subfield code="a">2020-02-17-12:42:55</subfield>
        </datafield>
        <datafield tag="980" ind1=" " ind2=" ">
            <subfield code="a">ARTICLE</subfield>
        </datafield>
    </record>

    
</collection>